readthroughSign in
Oct 1, 2026Trial update4 fact check notes

Vera Therapeutics posts ORIGIN 3 Phase 3 results for atacicept in IgA nephropathy

Trial record NCT04716231 shows a 39-percentage-point gap in UPCR reduction between atacicept and placebo at Week 36, with fewer serious adverse events on drug.

  • Atacicept, a Phase 3 candidate for IgA nephropathy (NCT04716231), posted Week 36 results on its primary endpoint. The study is titled "A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)," with the acronym ORIGIN 3.1
  • The trial enrolled 428 participants (actual)1 and lists Vera Therapeutics, Inc. as the lead sponsor1. Overall status is active not recruiting, with primary completion dated 2025-05-15 and study completion estimated for 2028-07.

Fact check notes

  • Checker's noteThe entry adds an unsupported temporal claim ('this week') not found in the source, which only provides specific posting dates (2026-10-01).
  • Sentence removedVera Therapeutics' ORIGIN 3 study updated with posted results this week.unsupported: The source gives a specific date, not a relative timeframe like 'this week'; no evidence supports or contradicts the 'this week' framing.
  • Sentence removedThe posted results showed a mean UPCR percent Change at Week 36 of -46 for Atacicept Dose 150mg versus -7 for Placebo to Match Atacicept (Part C/D).a figure with no citation
  • Sentence removedSerious adverse events were reported in 1 of 214 patients on Atacicept Dose 150mg versus 11 of 214 on Placebo to Match Atacicept (Part C/D).a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.